Skip to main content

Table 2 Summary of medication use at the time of coronary catheterization between patients with normal versus abnormal endothelial-independent and endothelial-dependent microvascular function

From: Coronary microvascular dysfunction is associated with poor glycemic control amongst female diabetics with chest pain and non-obstructive coronary artery disease

  CFRAdn Ratio > 2.5 CFRAdn Ratio ≤ 2.5 p value %ΔCBFAch > 50% %ΔCBFAch ≤ 50% p value
Metformin, n (%) 28 (35.0%) 18 (36.7%) 0.842 16 (31.4%) 30 (38.5%) 0.409
Thiazolidinedione, n (%) 5 (6.3%) 4 (8.2%) 0.682 2 (3.9%) 7 (9.0%) 0.253
Sulfonylurea, n (%) 12 (15.0%) 9 (18.4%) 0.617 7 (13.7%) 14 (18.0%) 0.522
Meglitinides, n (%) 0 (0.0%) 1 (2.0%) 0.163 0 (0.0%) 1 (1.3%) 0.315
Dipeptidyl peptidase-4 inhibitors, n (%) 2 (2.5%) 0 (0%) 0.165 1 (2.0%) 1 (1.3%) 0.763
Glucagon-like peptide 1 analog, n (%) 3 (3.8%) 0 (0%) 0.088 2 (3.9%) 1 (1.3%) 0.337
Insulin, n (%) 16 (20%) 13 (26.5%) 0.392 11 (21.6%) 18 (23.1%) 0.841
Dihydropyridines, n (%) 15 (18.8%) 8 (16.3%) 0.726 9 (17.7%) 14 (18.0%) 0.965
Diltiazem, n (%) 18 (22.5%) 7 (14.3%) 0.244 14 (27.5%) 11 (14.1%) 0.063
Statins, n (%) 42 (52.5%) 25 (51.0%) 0.870 24 (47.1%) 43 (55.1%) 0.370
Ranolazine, n (%) 2 (2.5%) 1 (2.0%) 0.866 2 (3.9%) 1 (1.3%) 0.337
ACE-Inhibitors or ARBs, n (%) 36 (45.0%) 25 (51.0%) 0.506 21 (41.2%) 40 (51.3%) 0.260
Beta blockers, n (%) 31 (38.8%) 21 (42.9%) 0.645 20 (39.2%) 32 (41.0%) 0.838
Aspirin, n (%) 51 (63.8%) 34 (69.4%) 0.511 34 (66.7%) 51 (65.4%) 0.881
l-Arginine, n (%) 4 (5.0%) 2 (4.1%) 0.809 4 (7.8%) 2 (2.6%) 0.169
Diuretics, n (%) 22 (27.5%) 21 (42.9%) 0.074 14 (27.5%) 29 (37.2%) 0.249
Nitrates, n (%) 22 (27.5%) 16 (32.7%) 0.535 17 (33.3%) 21 (26.9%) 0.437
  1. ACE-inhibitors, angiotensin converting enzyme-inhibitors; ARB, angiotensin receptor blockers; CFRAdn Ratio, coronary flow reserve ratio in response to adenosine; %ΔCBFAch, percentage change in coronary blood flow in response to acetylcholine